Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Testosterone regulates bone response to inflammation.

Steffens JP, Herrera BS, Coimbra LS, Stephens DN, Rossa C Jr, Spolidorio LC, Kantarci A, Van Dyke TE.

Horm Metab Res. 2014 Mar;46(3):193-200. doi: 10.1055/s-0034-1367031. Epub 2014 Feb 13.

2.

Prolactin decreases the expression ratio of receptor activator of nuclear factor kappaB ligand/osteoprotegerin in human fetal osteoblast cells.

Seriwatanachai D, Charoenphandhu N, Suthiphongchai T, Krishnamra N.

Cell Biol Int. 2008 Sep;32(9):1126-35. doi: 10.1016/j.cellbi.2008.04.026. Epub 2008 May 9.

PMID:
18556224
3.

RANKL/OPG ratio and DKK-1 expression in primary osteoblastic cultures from osteoarthritic and osteoporotic subjects.

Corrado A, Neve A, Macchiarola A, Gaudio A, Marucci A, Cantatore FP.

J Rheumatol. 2013 May;40(5):684-94. doi: 10.3899/jrheum.120845. Epub 2013 Mar 1.

PMID:
23457386
4.

Prolactin decreases expression of Runx2, osteoprotegerin, and RANKL in primary osteoblasts derived from tibiae of adult female rats.

Charoenphandhu N, Teerapornpuntakit J, Methawasin M, Wongdee K, Thongchote K, Krishnamra N.

Can J Physiol Pharmacol. 2008 May;86(5):240-8. doi: 10.1139/y08-037.

PMID:
18432284
5.

Osteoblast-Specific Overexpression of Human WNT16 Increases Both Cortical and Trabecular Bone Mass and Structure in Mice.

Alam I, Alkhouli M, Gerard-O'Riley RL, Wright WB, Acton D, Gray AK, Patel B, Reilly AM, Lim KE, Robling AG, Econs MJ.

Endocrinology. 2016 Feb;157(2):722-36. doi: 10.1210/en.2015-1281. Epub 2015 Nov 19.

6.

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.

Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ.

Bone. 2009 Oct;45(4):669-76. doi: 10.1016/j.bone.2009.06.011. Epub 2009 Jun 17.

PMID:
19539794
7.

Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL/OPG ratio.

Tudpor K, van der Eerden BC, Jongwattanapisan P, Roelofs JJ, van Leeuwen JP, Bindels RJ, Hoenderop JG.

Bone. 2015 Mar;72:14-22. doi: 10.1016/j.bone.2014.11.004. Epub 2014 Nov 18.

PMID:
25460576
8.

The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.

Enjuanes A, Ruiz-Gaspà S, Peris P, Ozalla D, Álvarez L, Combalia A, Martínez de Osaba MJ, Monegal A, Pares A, Guañabens N.

Endocrine. 2010 Feb;37(1):180-6. doi: 10.1007/s12020-009-9285-9. Epub 2009 Nov 24.

PMID:
20963568
9.

Dose-dependent effects of genistein on bone homeostasis in rats' mandibular subchondral bone.

Li YQ, Xing XH, Wang H, Weng XL, Yu SB, Dong GY.

Acta Pharmacol Sin. 2012 Jan;33(1):66-74. doi: 10.1038/aps.2011.136. Epub 2011 Nov 28.

10.

Bovine lactoferrin improves bone mass and microstructure in ovariectomized rats via OPG/RANKL/RANK pathway.

Hou JM, Xue Y, Lin QM.

Acta Pharmacol Sin. 2012 Oct;33(10):1277-84. doi: 10.1038/aps.2012.83. Epub 2012 Aug 20.

11.

Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: influence of osteotropic factors.

Tat SK, Pelletier JP, Lajeunesse D, Fahmi H, Duval N, Martel-Pelletier J.

Bone. 2008 Aug;43(2):284-91. doi: 10.1016/j.bone.2008.04.006. Epub 2008 Apr 26.

12.

17beta-Estradiol overcomes human myeloma RPMI8226 cell suppression of growth, ALP activity, and mineralization in rat osteoblasts and improves RANKL/OPG balance in vitro.

Li Q, Yu K, Tian X, Kong F, You Y, Chen Z, Zou P.

Leuk Res. 2009 Sep;33(9):1266-71. doi: 10.1016/j.leukres.2008.12.004. Epub 2009 Jan 22.

PMID:
19167063
13.

Omentin-1 exerts bone-sparing effect in ovariectomized mice.

Xie H, Xie PL, Luo XH, Wu XP, Zhou HD, Tang SY, Liao EY.

Osteoporos Int. 2012 Apr;23(4):1425-36. doi: 10.1007/s00198-011-1697-8. Epub 2011 Jul 14.

PMID:
21755404
14.

PTH differentially regulates expression of RANKL and OPG.

Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA.

J Bone Miner Res. 2004 Feb;19(2):235-44. Epub 2003 Dec 16.

15.

The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.

Peng S, Liu XS, Huang S, Li Z, Pan H, Zhen W, Luk KD, Guo XE, Lu WW.

Bone. 2011 Dec;49(6):1290-8. doi: 10.1016/j.bone.2011.08.031. Epub 2011 Sep 9.

PMID:
21925296
16.

Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study.

Tat SK, Pelletier JP, Vergés J, Lajeunesse D, Montell E, Fahmi H, Lavigne M, Martel-Pelletier J.

Arthritis Res Ther. 2007;9(6):R117.

17.

Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts.

Viereck V, Gründker C, Friess SC, Frosch KH, Raddatz D, Schoppet M, Nisslein T, Emons G, Hofbauer LC.

J Bone Miner Res. 2005 Nov;20(11):2036-43. Epub 2005 Jul 18.

18.

Effects of brucine on bone metabolism in multiple myeloma.

Ma Y, Zhao J, Wang Y, Li Z, Feng J, Ren H.

Mol Med Rep. 2012 Aug;6(2):367-70. doi: 10.3892/mmr.2012.920. Epub 2012 May 17.

PMID:
22614932
19.

Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.

Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.

J Bone Miner Res. 2005 Sep;20(9):1659-68. Epub 2005 May 2.

20.

Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.

Cao J, Venton L, Sakata T, Halloran BP.

J Bone Miner Res. 2003 Feb;18(2):270-7.

Supplemental Content

Support Center